Aditxt, Inc. Amortization of Intangible Assets
Aditxt, Inc. (ADTX) reported Amortization of Intangible Assets of $834 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-05-20
- Aditxt, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $834.00, a 0.12% increase year-over-year.
- Aditxt, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $833.00, a 0.00% change year-over-year.
- Aditxt, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $833.00, a 0.00% change year-over-year.
- Aditxt, Inc. amortization of intangible assets for the quarter ending 2025-06-30 was $834.00, a 0.12% increase year-over-year.
- Aditxt, Inc. amortization of intangible assets for fiscal 2025 was $3.33K, a 0.00% change from fiscal 2024.
- Aditxt, Inc. amortization of intangible assets for fiscal 2024 was $3.33K, a 96.90% decline from fiscal 2023.
- Aditxt, Inc. amortization of intangible assets for fiscal 2023 was $107.56K, a 0.52% increase from fiscal 2022.
- Aditxt, Inc. amortization of intangible assets for fiscal 2022 was $107.00K, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-03-31 | $834.00 10-Q · filed 2026-05-20 | $1.67K derived: sum of 2 quarters · filed 2026-05-20 | $2.50K derived: sum of 3 quarters · filed 2026-05-20 | $3.33K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $833.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.67K derived: sum of 2 quarters · filed 2026-03-31 | $2.50K derived: sum of 3 quarters · filed 2026-03-31 | $3.33K 10-K · filed 2026-03-31 |
| 2025-09-30 | $833.00 10-Q · filed 2025-11-18 | $1.67K derived: sum of 2 quarters · filed 2025-11-18 | $2.50K 10-Q · filed 2025-11-18 | $3.33K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $834.00 10-Q · filed 2025-08-14 | $1.67K 10-Q · filed 2025-08-14 | $2.50K derived: sum of 3 quarters · filed 2026-05-20 | $3.33K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $833.00 10-Q · filed 2026-05-20 | $1.67K derived: sum of 2 quarters · filed 2026-05-20 | $2.50K derived: sum of 3 quarters · filed 2026-05-20 | $3.33K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $833.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.67K derived: sum of 2 quarters · filed 2026-03-31 | $2.50K derived: sum of 3 quarters · filed 2026-03-31 | $3.33K 10-K · filed 2026-03-31 |
| 2024-09-30 | $833.00 10-Q · filed 2025-11-18 | $1.67K derived: sum of 2 quarters · filed 2025-11-18 | $2.50K 10-Q · filed 2025-11-18 | $29.80K derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $833.00 10-Q · filed 2025-08-14 | $1.67K 10-Q · filed 2025-08-14 | $28.97K derived: sum of 3 quarters · filed 2025-08-14 | $55.72K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $833.00 10-Q · filed 2025-05-15 | $28.14K derived: sum of 2 quarters · filed 2025-05-15 | $54.89K derived: sum of 3 quarters · filed 2025-05-15 | $81.64K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $27.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $54.06K derived: sum of 2 quarters · filed 2025-03-31 | $80.81K derived: sum of 3 quarters · filed 2025-03-31 | $107.56K 10-K · filed 2025-03-31 |
| 2023-09-30 | $26.75K 10-Q · filed 2024-11-18 | $53.50K derived: sum of 2 quarters · filed 2024-11-18 | $80.25K 10-Q · filed 2024-11-18 | $107.00K derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $26.75K 10-Q · filed 2024-08-19 | $53.50K 10-Q · filed 2024-08-19 | $80.25K derived: sum of 3 quarters · filed 2024-08-19 | $107.00K derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $26.75K 10-Q · filed 2024-05-20 | $53.50K derived: sum of 2 quarters · filed 2024-05-20 | $80.25K derived: sum of 3 quarters · filed 2024-05-20 | $107.00K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $26.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $53.50K derived: sum of 2 quarters · filed 2024-04-16 | $80.25K derived: sum of 3 quarters · filed 2024-04-16 | $107.00K 10-K · filed 2024-04-16 |
| 2022-09-30 | $26.75K 10-Q · filed 2023-11-14 | $53.50K derived: sum of 2 quarters · filed 2023-11-14 | $80.25K 10-Q · filed 2023-11-14 | $107.22K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $26.75K 10-Q · filed 2022-08-15 | $53.50K 10-Q · filed 2023-08-14 | $80.47K derived: sum of 3 quarters · filed 2023-04-17 | $107.44K derived: sum of 4 quarters · filed 2023-04-17 |
| 2022-03-31 | $26.75K 10-Q · filed 2022-05-16 | $53.72K derived: sum of 2 quarters · filed 2023-04-17 | $80.69K derived: sum of 3 quarters · filed 2023-04-17 | $107.37K derived: sum of 4 quarters · filed 2023-04-17 |
| 2021-12-31 | $26.97K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $53.94K derived: sum of 2 quarters · filed 2023-04-17 | $80.62K derived: sum of 3 quarters · filed 2023-04-17 | $107.00K 10-K · filed 2023-04-17 |
| 2021-09-30 | $26.97K 10-Q · filed 2022-11-14 | $53.65K derived: sum of 2 quarters · filed 2022-11-14 | $80.03K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $26.68K 10-Q · filed 2022-08-15 | $53.06K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $26.38K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |